A combination of hypothalamic phospholipid liposomes with trazodone for treatment of depression. An open controlled study.
In an open controlled trial of 48 patients with major depression illness (according to DSM-III), the patients were randomly assigned to 2 groups. One group of 25 patients was treated with 200-300 mg/day of trazodone and a second group of 23 patients was treated with 200-300 mg/day trazodone plus 1 ampoule (corresponding to 1000 gamma of lipidic phosphorous) twice daily of hypothalamic phospholipids (HPL). The effectiveness of treatment was evaluated by the Hamilton Rating Scale for Depression (HRSD). Side effects of treatment with trazodone were looked for by measuring systolic and diastolic blood pressure and heart rate and from EEG made before and on the 7th and 30th days of treatment. Combination with HPL shortened the typical latency of action of the antidepressant trazodone, definitely improved the subjective symptoms, especially the psychosomatic symptoms, on the HRDS and decreased the incidence of such side effects of trazodone as hypertension, reflex tachycardia and asthenia.
Giannelli
A
A
Niguarda Cà Granda Hospital, Vergani Psychiatric Service, Milan, Italy.
Rabboni
M
M
Zarattini
F
F
Malgeri
C
C
Magnolfi
G
G
D000328:Adult; D000368:Aged; D001143:Arousal / Q000187:drug effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000523:psychology / Q000628:therapy*; D005260:Female; D006801:Humans; D007031:Hypothalamus / Q000502:physiology*; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008081:Liposomes / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000008:administration & dosage*; D011569:Psychiatric Status Rating Scales; D014196:Trazodone / Q000008:administration & dosage*
D008081:Liposomes; D010743:Phospholipids; D014196:Trazodone